Financials Apontis Pharma AG Deutsche Boerse AG

Equities

APPH

DE000A3CMGM5

Pharmaceuticals

Market Closed - Deutsche Boerse AG Other stock markets 03:41:18 2024-04-26 pm EDT			5-day change	1st Jan Change
7.98 ^EUR	0.00%		+3.91%	+70.51%

Apr. 05	Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	MT
Mar. 28	Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Valuation

Fiscal Period: December	2021	2022	2023	2024	2025	2026
Capitalization ¹	170	69.7	39.57	68.97	-	-
Enterprise Value (EV) ¹	140.2	33.35	39.57	57.71	56.97	50.67
P/E ratio	-227 x	25.9 x	-3.57 x	69 x	19.1 x	10 x
Yield	-	-	-	-	-	-
Capitalization / Revenue	3.32 x	1.25 x	1.07 x	1.35 x	1.17 x	0.98 x
EV / Revenue	2.74 x	0.6 x	1.07 x	1.13 x	0.97 x	0.72 x
EV / EBITDA	28.8 x	5.99 x	-2.98 x	16.8 x	7.3 x	3.77 x
EV / FCF	79 x	4.31 x	-	-6.58 x	74.3 x	8.04 x
FCF Yield	1.27%	23.2%	-	-15.2%	1.35%	12.4%
Price to Book	4.18 x	1.64 x	-	2.24 x	2.02 x	1.69 x
Nbr of stocks (in thousands)	8,500	8,500	8,330	8,330	-	-
Reference price ²	20.00	8.200	4.750	8.280	8.280	8.280
Announcement Date	3/30/22	3/30/23	3/28/24	-	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	39.24	51.18	55.73	36.96	51.07	58.83	70.13
EBITDA ¹	-	4.862	5.569	-13.28	3.433	7.8	13.43
EBIT ¹	-	3.116	3.876	-15.16	1.433	5.067	9.567
Operating Margin	-	6.09%	6.96%	-41.02%	2.81%	8.61%	13.64%
Earnings before Tax (EBT) ¹	-	0.2483	3.828	-14.85	1.433	5.067	9.6
Net income ¹	-1.183	-0.7452	2.689	-11.3	1.033	3.7	7.033
Net margin	-3.01%	-1.46%	4.82%	-30.58%	2.02%	6.29%	10.03%
EPS ²	-	-0.0880	0.3163	-1.330	0.1200	0.4333	0.8267
Free Cash Flow ¹	-	1.773	7.742	-	-8.767	0.7667	6.3
FCF margin	-	3.46%	13.89%	-	-17.17%	1.3%	8.98%
FCF Conversion (EBITDA)	-	36.48%	139.02%	-	-	9.83%	46.9%
FCF Conversion (Net income)	-	-	287.93%	-	-	20.72%	89.57%
Dividend per Share ²	-	-	-	-	-	-	-
Announcement Date	4/29/21	3/30/22	3/30/23	3/28/24	-	-	-

¹EUR in Million²EUR

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2021 S1	2021 Q3	2022 S1	2024 Q1
Net sales ¹	24.01	12.69	-	10.5
EBITDA ¹	-	1.566	-	-0.1
EBIT ¹	-	1.227	-	-0.5
Operating Margin	-	9.67%	-	-4.76%
Earnings before Tax (EBT)	-	-	2.389	-
Net income	-2.197	-	2.351	-
Net margin	-9.15%	-	-	-
EPS	-	-	-	-
Dividend per Share	-	-	-	-
Announcement Date	8/11/21	11/18/21	8/11/22	-

¹EUR in Million

Estimates

Balance Sheet Analysis

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-
Net Cash position ¹	-	29.8	36.3	-	11.3	12	18.3
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow ¹	-	1.77	7.74	-	-8.77	0.77	6.3
ROE (net income / shareholders' equity)	-	7.95%	6.54%	-	3.33%	10.9%	18.2%
ROA (Net income/ Total Assets)	-	-	4.72%	-	2%	6.3%	11.6%
Assets ¹	-	-	56.99	-	51.67	58.73	60.63
Book Value Per Share ²	-	4.790	4.990	-	3.700	4.100	4.900
Cash Flow per Share	-	-	-	-	-	-	-
Capex ¹	-	1.66	3.28	-	4.17	5.7	4.9
Capex / Sales	-	3.24%	5.88%	-	8.16%	9.69%	6.99%
Announcement Date	4/29/21	3/30/22	3/30/23	3/28/24	-	-	-

¹EUR in Million²EUR

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Apontis Pharma AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.28 EUR

Average target price

17.5 EUR

Spread / Average Target

+111.35%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals